miRNAs in insulin resistance and diabetes-associated pancreatic cancer: The 'Minute and Miracle' molecule moving as a monitor in the 'genomic galaxy'

Current Drug Targets

Volumn 14, Issue 10, 2013, Pages 1110-1117

  Chakraborty, Chiranjib ^a   George Priya Doss, C ^b   Bandyopadhyay, Sanghamitra ^c  

^a GALGOTIAS UNIVERSITY   (India)

^b VIT UNIVERSITY   (India)

^c INDIAN STATISTICAL INSTITUTE   (India)

Author keywords

Insulin resistance; Insulin IGF mTOR signaling pathway; miRNA; Pancreatic cancer; Type 2 diabetes

Indexed keywords

ADRENOMEDULLIN; MICRORNA; MICRORNA 1; MICRORNA 101; MICRORNA 103; MICRORNA 107; MICRORNA 124A2; MICRORNA 126; MICRORNA 128A; MICRORNA 139; MICRORNA 145; MICRORNA 146A; MICRORNA 155; MICRORNA 195; MICRORNA 19A; MICRORNA 200; MICRORNA 21; MICRORNA 221; MICRORNA 29A; MICRORNA 29B; MICRORNA 29C; MICRORNA 34; MICRORNA 34A; MICRORNA 375; MICRORNA 7; MICRORNA 9; MICRORNA 96; MICRORNA 99; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CANCER GROWTH; COLORECTAL CANCER; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MICRORNAS; PANCREAS; PANCREATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84881340355     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113149990182     Document Type: Article

References (139)

1. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the doomsday scenario be averted? J Intern Med 2000; 247: 301-10.
2. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-7.
3. World Diabetes Population Hits 366 Million (http://www.mydiabetes. in/news/2011/Sep/world-diabetes-population-hits-366- million-91552382.html).
4. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995- 2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-31.
5. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-21.
6. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
7. Chakraborty C, Roy SS, Hsu MJ, Agoramoorthy G. Landscape Mapping of Functional Proteins in Insulin Signal Transduction and Insulin Resistance: A Network-Based Protein-Protein Interaction Analysis. PLoS ONE 2011; 6(1): e16388.
8. McCarthy MI, Zeggini E. Genome-wide association studies in type 2 diabetes. Curr Diab Rep 2009; 9: 164-71.
9. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004; 53: S16-21.
10. Bonelli L, Aste H, Bovo P, et al. Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control study in northern Italy. Pancreas 2003; 27: 143-9.
11. Frye JN, Inder WJ, Dobbs BR, Frizelle FA. Pancreatic cancer and diabetes: is there a relationship? A case-controlled study. Aust N Z J Surg 2000; 70: 722-4.
12. Stolzenber-Solomon RZ, Pietinen P, Taylor PR, Virtamo J, Albanes D. A prospective study of medical conditions, anthropometry, physical activity, and pancreatic cancer in male smokers (Finland). Cancer Causes Control 2002; 13: 417-26
13. Lin Y, Tamakoshi A, Kawamura T, et al. Risk of pancreatic cancer in relation to alcohol drinking, coffee consumption and medical history: findings from the Japan collaborative cohort study for evaluation of cancer risk. Int J Cancer 2002; 99: 742-6.
14. Coughlin SS, Calle EE, Patel AV, Thun MJ. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 2000; 11: 915-23.
15. Gapstur SM, Gann PH, Lowe W, et al. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000; 283: 2552-8.
16. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
17. Muniraj T, Chari ST. Diabetes and pancreatic cancer. Minerva Gastroenterol Dietol 2012; 58(4): 331-45.
18. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
19. Calle EE, Murphy TK, Rodriguez C, Thun MJ, Heath CW Jr. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control 1998; 9: 403-10.
20. Li D. Diabetes and pancreatic cancer. Mol Carcinog 2012; 51: 64-74.
21. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA: a cancer journal for clinicians 2010; 60(4): 207-221.
22. Permert J, Ihse I, Jorfeldt L, et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993; 159: 101-7.
23. Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 2013; 10(7): 423-33.
24. Perrin MC, Terry MB, Kleinhaus K, et al. Gestational diabetes as a risk factor for pancreatic cancer: a prospective cohort study. BMC Med 2007; 5: 25.
25. Chakraborty C. Biochemical and molecular basis of insulin resistance. Curr Protein Pept Sci 2006; 7: 113-21.
26. Soumaya K. Molecular mechanisms of insulin resistance in diabetes. Adv Exp Med Biol 2012; 771: 240-51.
27. DeFronzo RA. The triumvirate: b-cell, muscle, liver. A Collusion responsible for NIDDM. Diabetes 1988; 37: 667-87.
28. Defronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-95.
29. Arcidiacono B, Iiritano S, Nocera A, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res 2012; 2012: 789174.
30. Grosshans H, Slack FJ. microRNAs: small is plentiful. J Cell Biol 2002; 156: 17-21.
31. Lim LP, Glasner ME, Yekta S, Burge CB, Bartel DP. Vertebrate microRNA genes. Science 2003; 299: 1540.
32. Shukla GC, Singh J, Barik S. MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Mol Cell Pharmacol 2011; 3: 83-92.
33. Kim VN, Nam JW. Genomics of microRNA. Trends Genet 2006; 22: 165-73.
34. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
35. Carleton M, Cleary MA, Linsley PS. MicroRNAs and cell cycle regulation. Cell Cycle 2007; 6: 2127-32.
36. Harfe BD. MicroRNAs in vertebrate development. Curr Opin Genet Dev 2005; 15: 410-5.
37. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001; 294: 858-62.
38. Boehm M, Slack FJ. MicroRNA control of lifespan and metabolism. Cell Cycle 2005; 5: 837-40.
39. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-69.
40. Landthaler M, Yalcin A, Tuschl T. The human DiGeorge syndrome critical region gene 8 and its D. melanogaster homolog are required for miRNA biogenesis. Curr Biol 2004; 14: 2162-67.
41. Jin P, Alisch RS, Warren ST. RNA and microRNAs in fragile X mental retardation. Nat Cell Biol 2004; 6: 1048-53.
42. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
43. Volinia S, Calin G, Liu CG, et al. A microRNA expression signature in human solid tumors defines cancer targets. Proc Natl Acad Sci USA 2006; 103: 2257-61.
44. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27: S5-S10.
45. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009; 16: 1103-23.
46. Yang X, Ko GTC, So WY, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes 2010; 59: 1254-60.
47. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137: 482-8.
48. Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 2011; 47: 1928-37.
49. Grant SF, Hakonarson H, Schwartz S. Can the genetics of type 1 and type 2 diabetes shed light on the genetics of latent autoimmune diabetes in adults? Endocr Rev 2010; 31: 183-93.
50. Donath MY, Ehses JA, Maedler K, et al. Mechanisms of beta-cell death in type 2 diabetes. Diabetes 2005; 54: S108-13.
51. Gullo L, Pezzilli R, Morselli-Labate A. Diabetes and the risk of pancreatic cancer. N Engl J Med 1994; 79: 1223-31.
52. Vecchis CL, Negri E, Franceschi S, D'Avanzo B, Boyle P. Diabetes and pancreatic cancer risk. Int J Pancretol 1994; 16: 81-4.
53. Permert J, Ihse I, Jorfeldt L, von-Schenck H, Arnquist HJ, Larsson J. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993; 80: 1047-50.
54. Ding X-Z, Flatt PR, Permert J, Adrian TE. Pancreatic cancer cells selectively stimulate co-cultured islet -cells to secrete amylin. Gastroenterology 1998; 114: 130-8.
55. Li J, Adrian TE. A factor from pancreatic and colon cancer cells stimulates glucose uptake and lactate production in myoblasts. Biochem Biophys Res Commun 1999; 260: 626-33.
56. Aggarwal G, Ramachandran V, Javeed N, et al. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in _ cells and mice. Gastroenterology 2012; 143: 1510-7.
57. Chari ST. Diabetes and Pancreatic Cancer: A Complex Relationship. 2013 Gastrointestinal Cancers Symposium Proceedings 2013; 33-34.
58. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002; 3: 298-302.
59. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M. Insulin-like growth factor I overexpression in human pancreatic cancer: Evidence for autocrine and paracrine roles. Cancer Res 1995; 55: 2007-11.
60. King ER, Wong KK. Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Pat Anticancer Drug Discov 2012; 7(1): 14-30.
61. Pacher M, Seewald MJ, Mikula M, et al. Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells. Carcinogenesis 2007; 28: 49-59.
62. Accili D, Kido Y, Nakae J. Genetics of Type 2 Diabetes Insight from Targeted Mouse Mutants. Current molecular medicine 2001; 1(1): 9-23.
63. Chakraborty C, Agoramoorthy G, Hsu MJ. Exploring the evolutionary relationship of insulin receptor substrate family using computational biology. PLoS ONE 2011; 6(2): e16580.
64. Chakraborty C, George Priya Doss C, Bandyopadhyay S, Sarkar BK, Syed Haneef SA. Mapping the Structural Topology of IRS Family Cascades through Computational Biology. Cell Biochem Biophys 2013 Jun 4. [Epub ahead of print].
65. Chakraborty C, Bandyopadhyay S, Maulik U, Agoramoorthy G. Topology mapping of insulin-regulated glucose transporter GLUT4 using computational biology. Cell Biochemistry and Biophysics 2013 May 23. [Epub ahead of print].
66. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nature Rev Cancer 2008; 8: 915-28.
67. Nair PN, De Armond DT, Adamo ML, Strodel WE, Freeman JW. Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Oncogene. 2001; 20: 8203-14.
68. Rieder S, Michalski CW, Friess H, Kleeff J. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer. Anticancer Agents Med Chem 2011; 11(5): 427-33.
69. Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3- kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci USA 2000; 97: 1749-53.
70. Hammel PR, Vilgrain V, Terris B, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d_Etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000; 119: 1087-95.
71. Advani SH. Targeting mTOR pathway: A new concept in cancer therapy. Indian J Med Paediatr Oncol 2010; 31: 132-6.
72. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011; 121: 1231-41.
73. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006; 66(15): 7390-4.
74. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
75. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-9.
76. Sonoki T, Iwanaga E, Mitsuya H, Asou N. Insertion of microRNA- 125b-1, a human homologue of lin-4, into a rearranged immunoglobulin heavy chain gene locus in a patient with precursor B-cell acute lymphoblastic leukemia. Leukemia 2005; 19: 2009-10.
77. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64: 3753-6.
78. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 2008; 7: 464-73.
79. Kowarsch A, Preusse M, Marr C, Theis FJ. miTALOS: analyzing the tissue-specific regulation of signaling pathways by human and mouse microRNAs. RNA 2011; 17: 809-19.
80. Knowlton DL, Tang K, Henstock PV, Subramanian RR. miRAN alterations modify kinase activation in the IGF-1 pathway and correlate with colorectal cancer stage and progression in patients. J Cancer 2011; 2: 490-502.
81. Li Y, VandenBoom TG, Kong D, Wang Z, Ali S, Philip PA, Sarkar FH. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabineresistant pancreatic cancer cells. Cancer research 2009; 69: 6704-12.
82. Cobelli C, Renard E, Kovatchev B. Artificial pancreas: Past, present, future. Diabetes 2011; 60: 2672-82.
83. Donath MY, Ehses JA, Maedler K, et al. Mechanisms of beta-cell death in type 2 diabetes. Diabetes 2005; 54: S108-S113.
84. Costes S, Langen R, Gurlo T, Matveyenko AV, Butler PC. β-Cell failure in type 2 diabetes: a case of asking too much of too few? Diabetes 2013; 62: 327-35.
85. Osman MA, Sarkar FH, Rodriguez-Boulan E. A molecular rheostat at the interface of cancer and diabetes. Biochim Biophys Acta 2013; 1836: 166-76.
86. Poy MN, Eliasson L, Krutzfeldt J, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004; 432: 226-30.
87. Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nature Genetics 2005; 37: 495-500.
88. Lovis P, Gattesco S, Regazzi R. Regulation of the expression of components of the exocytotic machinery of insulin-secreting cells by microRNAs. Biological Chemistry 2008; 389: 305-12.
89. Poy MN, Hausser J, Trajkovski M. miR-375 maintains normal pancreatic alpha- and beta-cell mass. PNAS 2009; 106: 5813-8.
90. Zhao H, Guan J, Lee HM, et al. Upregulated pancreatic tissue microRNA- 375 associates with human type 2 diabetes through beta-cell deficit and islet amyloid deposition. Pancreas 2010; 39: 843-6.
91. Correa-Medina M, Bravo-Egana V, Rosero S, et al. MicroRNA miR-7 is preferentially expressed in endocrine cells of the developing and adult human pancreas. Gene Expr Patterns 2009; 9: 193-9.
92. Baroukh N, Ravier MA, Loder MK. MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. The Journal of Biological Chemistry 2007; 282: 19575-88.
93. Herrera BM, Lockstone HE, Taylor JM, et al. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 2010; 53: 1099-1109.
94. Lynn FC, Skewes-Cox P, Kosaka Y, et al. MicroRNA expression is required for pancreatic islet cell genesis in the mouse. Diabetes 2007; 56: 2938-45.
95. Huang B, Qin W, Zhao B, et al. MicroRNA expression profiling in diabetic GK rat model. Acta Biochim Biophys Sin (Shanghai) 2009; 41: 472-7.
96. Warshamana-Greene GS, Litz J, Buchdunger E, et al. The insulinlike growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 2005; 11: 1563-71.
97. Jones HE, Goddard L, Gee JM, et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells Endocr Relat Cancer 2004; 11: 793-81.
98. Ma J, Sawai H, Matsuo Y, et al. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells. The Journal of surgical research 2010; 160: 90.
99. Zhao X, Dou W, He L, et al. MicroRNA-7 functions as an antimetastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene 2013; 32: 1363-72.
100. Shen K, Liang Q, Xu K, et al. MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem Pharmacol 2012; 84: 320-30.
101. Law PT, Ching AK, Chan AW, et al. MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis 2012; 33: 1134-41.
102. Glauser DA, Schlegel W. FoxO proteins in pancreatic β-cells as potential therapeutic targets in diabetes. Expert Review of Endocrinology and Metabolism 2008; 3: 175-85.
103. Ali AS, Ali S, Ahmad A, et al. Expression of microRNAs: potential molecular link between obesity, diabetes and cancer. Obesity Reviews 2011; 12: 1050-62.
104. Motohashi N, Alexander MS, Shimizu-Motohashi Y, et al. Regulation of IRS1/Akt insulin signaling by microRNA-128a during myogenesis. J Cell Sci 2013.
105. He J, Li Y, Yang X, et al. The feedback regulation of PI3K-miR- 19a, and MAPK-miR-23b/27b in endothelial cells under shear stress. Molecules 2012; 18: 1-13.
106. Chen T, Ding G, Jin Z, et al. Insulin ameliorates miR-1-induced injury in H9c2 cells under oxidative stress via Akt activation. Mol Cell Biochem 2012; 369: 167-74.
107. Lempiäinen H, Halazonetis TD. Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J 2009; 28: 3067-73.
108. Wullschleger S, Loewith R, Hall M. TOR signaling in growth and metabolism. Cell 2006; 124: 471-84.
109. Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012; 335: 1638-43.
110. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-45.
111. Beevers C, Li F, Liu L, Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells Int J Cancer 2006; 119: 757-64.
112. Totary-Jain H, Marks AR. MicroRNAs and the cellular response to rapamycin: potential role in diagnosis and therapy. Cell Cycle 2013; 12: 861-2.
113. Jin Y, Tymen SD, Chen D, et al. MicroRNA-99 Family Targets AKT/mTOR Signaling Pathway in Dermal Wound Healing. PLoS One 2013; 8(5): e64434.
114. Olivieri F, Rippo MR, Monsurro V, et al. MicroRNAs linking inflamm-aging, cellular senescence and cancer. Ageing Res Rev 2013; S1568-1637(13)00023-8.
115. Nelson PT, Baldwin DA, Scearce LM, et al. Microarray-based, high-throughput gene expression profiling of microRNAs. Nature Methods 2004; 1: 155-61.
116. Thomson JM, Parker J, Perou CM, Hammond SM. A custom microarray platform for analysis of microRNA gene expression. Nature Methods 2004; 1: 47-53.
117. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-1801.
118. Ansari D, Chen BC, Dong L, Zhou MT, Andersson R. Pancreatic cancer: translational research aspects and clinical implications. World J Gastroenterol 2012; 18: 1417-24.
119. Rachagani S, Kumar S, Batra SK. MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Lett 2010; 292: 8-16.
120. Giovannetti E, van der Velde A, Funel N, et al. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR- 211 in pancreatic cancer. PLoS One 2012; 7: e49145.
121. Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med 2012; 6: 597-612.
122. Ali S, Ahmad A, Banerjee S, et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010; 70: 3606-17.
123. Roldo C, Missiaglia E, Hagan JP, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006; 24: 4677-84.
124. Bommer GT, Gerin I, Feng Y, et al. p53- mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17: 1298-307.
125. He L, He X, Lim LP, et al. A microRNA component of the p53 tumor suppressor network. Nature 2007; 447: 1130-4.
126. Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells. PLoS ONE 2009; 4: e6816.
127. Park JK, Lee EJ, Esau C, Schmittgen TD. Antisense Inhibition of microRNA-21 or -221 Arrests Cell Cycle, Induces Apoptosis, and Sensitizes the Effects of Gemcitabine in Pancreatic Adenocarcinoma. Pancreas 2009; 38: e190-9.
128. Qazi AM, Gruzdyn O, Semaan A, et al. Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA- 101. Surgery 2012; 152: 704-11.
129. Joglekar MV, Joglekar VM, Hardikar AA. Expression of isletspecific microRNAs during human pancreatic development. Gene Expr Patterns 2009; 9: 109-13.
130. Plaisance V, Abderrahmani A, Perret-Menoud V, et al. MicroRNA- 9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J Biol Chem 2006; 281: 26932-42.
131. Ramachandran D, Roy U, Garg S, et al. Sirt1 and mir-9 expression is regulated during glucose-stimulated insulin secretion in pancreatic beta-islets. FEBS J 2011; 278: 1167-74.
132. Lovis P, Gattesco S, Regazzi R. Regulation of the expression of components of the exocytotic machinery of insulin-secreting cells by microRNAs. Biol Chem 2008; 389: 305-12.
133. Roggli E, Britan A, Gattesco S, et al. Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells. Diabetes 2010; 59: 978-86.
134. Kong L, Zhu J, Han W, et al. Significance of serum microRNAs in prediabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol 2011; 48: 61-9.
135. Lovis P, Gattesco S, Regazzi R. Regulation of the expression of components of the exocytotic machinery of insulin-secreting cells by microRNAs. Biol Chem 2008; 389: 305-12.
136. Yu XY, Song YH, Geng YJ, et al. Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1. Biochem Biophys Res Commun 2008; 376: 548-52.
137. Elia L, Contu R, Quintavalle M, et al. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 2009; 120: 2377-85.
138. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107(6): 810-7.
139. Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009; 16: 23-9.